| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2004 | WO2004026226A2 Compounds, compositions and methods |
| 04/01/2004 | WO2004026225A2 Therapeutic agents and corresponding treatments |
| 04/01/2004 | WO2004026224A2 Process for preparing prostaglandin derivatives and starting materials for the same |
| 04/01/2004 | WO2004026218A2 Multi-use vessels for vitamin d formulations |
| 04/01/2004 | WO2004026118A2 Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| 04/01/2004 | WO2004026116A2 Use of etodoclac to treat hyperplasia |
| 04/01/2004 | WO2004026107A2 Kits and methods for assessing skin health |
| 04/01/2004 | WO2004026047A1 Functional foods/drinks containing antiallergic component |
| 04/01/2004 | WO2004026035A1 Organic acids incorporated edible antimicrobial films |
| 04/01/2004 | WO2004018482A3 C6- and c9-substituted chromeno[4, 3-c]isoxazoline derivatives and their use as anti-depressants |
| 04/01/2004 | WO2004017998A3 Topical emulsion- gel composition comprising diclofenac sodium |
| 04/01/2004 | WO2004013298A3 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections |
| 04/01/2004 | WO2004012700A3 Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release |
| 04/01/2004 | WO2004012699A3 Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent |
| 04/01/2004 | WO2004009074A3 A multi-ring regulator of gut motility and food intake |
| 04/01/2004 | WO2004007723A3 Genes |
| 04/01/2004 | WO2004006934A3 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours |
| 04/01/2004 | WO2004006933A3 Crystal forms of olanzapine and processes for their preparation |
| 04/01/2004 | WO2004006884A3 Process for providing a stable crystalline form of salbutamol |
| 04/01/2004 | WO2004006832A3 Methods and compounds for reducing biofilm formation |
| 04/01/2004 | WO2004005478A3 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 04/01/2004 | WO2004002401A3 Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents |
| 04/01/2004 | WO2004002399A3 Use of gaba-c receptor antagonists for the treatment of myopia |
| 04/01/2004 | WO2004000354A3 Method of treating the syndrome of lipodystrophy |
| 04/01/2004 | WO2003106630A3 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| 04/01/2004 | WO2003106498A3 Ox40 (=cd134) receptor agonistic and therapeutic use |
| 04/01/2004 | WO2003106425A3 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity |
| 04/01/2004 | WO2003103644A3 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 04/01/2004 | WO2003103613A3 Induction of insulin expression |
| 04/01/2004 | WO2003101932A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 04/01/2004 | WO2003099830A3 Cardiolipin compositions, methods of preparation and use |
| 04/01/2004 | WO2003099819A3 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics |
| 04/01/2004 | WO2003099771A3 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| 04/01/2004 | WO2003099284B1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| 04/01/2004 | WO2003099281A3 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes |
| 04/01/2004 | WO2003099256A3 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES) |
| 04/01/2004 | WO2003097799A3 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS |
| 04/01/2004 | WO2003097658A3 Compounds and methods for inhibiting selectin-mediated function |
| 04/01/2004 | WO2003097633A8 2-thio-substituted imidazole derivatives and their use in pharmaceutics |
| 04/01/2004 | WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands |
| 04/01/2004 | WO2003095471A3 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation |
| 04/01/2004 | WO2003094968A3 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases |
| 04/01/2004 | WO2003094905A8 Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders |
| 04/01/2004 | WO2003094864A3 Novel polyol-glycoside compositions for the skin |
| 04/01/2004 | WO2003092767A3 A method for inhibiting platelet aggregation |
| 04/01/2004 | WO2003092645A3 Cosmetic composition comprising monosaccharides or polysaccharides____________________________________ |
| 04/01/2004 | WO2003092628A3 High-quality lipids and methods for producing by enzymatic liberation from biomass |
| 04/01/2004 | WO2003091694A3 Method for assay of cognition and memory based on low frequency stimulation |
| 04/01/2004 | WO2003090737A3 Methods and compositions for treatment of cancer pain |
| 04/01/2004 | WO2003089449A3 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity |
| 04/01/2004 | WO2003088927A3 Novel curcumin analogues and uses thereof |
| 04/01/2004 | WO2003086452A3 Methods of enhancing lysosomal storage disease therapy |
| 04/01/2004 | WO2003086412A3 Polyphosphonate derivatives for toothpaste compositions |
| 04/01/2004 | WO2003086341A3 Aminophenylbenzothiazole compounds |
| 04/01/2004 | WO2003084943A3 Terphenyl derivatives, preparation thereof, compositions containing same |
| 04/01/2004 | WO2003084540A3 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 04/01/2004 | WO2003084518A3 Oral suspension of active principle microcapsules |
| 04/01/2004 | WO2003084517A3 Oral suspension of amoxicillin capsules |
| 04/01/2004 | WO2003084481A3 Biological affinity based delivery systems |
| 04/01/2004 | WO2003084343A3 Method and dietary composition for improving fat digestibility |
| 04/01/2004 | WO2003082874A3 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 04/01/2004 | WO2003082314A3 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 04/01/2004 | WO2003082256A3 Use of a cb1 cannabinoid receptor antagonist for producing medicaments which are useful for treating sexual behaviour problems and/or for improving sexual performances |
| 04/01/2004 | WO2003081238A3 Cytocapacity test |
| 04/01/2004 | WO2003079998A3 Treatment of diseases involving defective gap junctional communication |
| 04/01/2004 | WO2003079988A3 Use of tagatose in laxatives |
| 04/01/2004 | WO2003077893A3 Compositions for treating digestive functional pathologies |
| 04/01/2004 | WO2003075953A3 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 04/01/2004 | WO2003075932A8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 04/01/2004 | WO2003075834A3 Activated protein c formulations |
| 04/01/2004 | WO2003074078A3 Cg3842 homologous proteins involved in the regulation of energy homeostasis |
| 04/01/2004 | WO2003072029A3 Methods of extending corneal graft survival |
| 04/01/2004 | WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid |
| 04/01/2004 | WO2003068148A3 Treatment of sleep disorders using sleep target modulators |
| 04/01/2004 | WO2003066021A3 Drug nanoparticles with lysozyme surface stabiliser |
| 04/01/2004 | WO2003064617A3 Pestalotiopsis microsporia isolates and compounds derived therefrom |
| 04/01/2004 | WO2003063844A3 Treatment of rheumatoid arthritis using imatinie |
| 04/01/2004 | WO2003061654A9 Pramipexole for the treatment of hiv dementia |
| 04/01/2004 | WO2003059874A3 Aromatic thioether liver x-receptor modulators |
| 04/01/2004 | WO2003057205A3 Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs |
| 04/01/2004 | WO2003057012A8 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 04/01/2004 | WO2003054226A3 Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
| 04/01/2004 | WO2003049675A3 Treating muscle wasting with selective androgen receptor modulators |
| 04/01/2004 | WO2003048147A3 PREPARATION OF CIS-FUSED 3,3a,8,12b-TETRAHYDRO-2H-DIBENZO[3,4:6,7]CYCLOHEPTA[1,2-b]FURAN DERIVATIVES |
| 04/01/2004 | WO2003041642A3 Polymeric thiol-linked prodrugs employing benzyl elimination systems |
| 04/01/2004 | WO2003028692A8 Acne treatment using oleanolic acid |
| 04/01/2004 | WO2003028652A3 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| 04/01/2004 | WO2003026635A3 Improved method of treating the syndrome of type 2 diabetes in humans |
| 04/01/2004 | WO2003016563A3 Novel molecular target for neurotoxicity |
| 04/01/2004 | WO2003009842A8 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/01/2004 | WO2003008410A8 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 04/01/2004 | WO2002102314A3 Purine inhibitors of phosphodiesterase (pde) 7 |
| 04/01/2004 | WO2002098852A8 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins |
| 04/01/2004 | WO2002089798A3 Method and compositions for treating migraines |
| 04/01/2004 | WO2002085897A9 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 04/01/2004 | WO2002083847A3 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 04/01/2004 | WO2002076402A3 Fatty amine drug conjugates |
| 04/01/2004 | WO2002069900A3 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 04/01/2004 | WO2002066480A3 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 04/01/2004 | WO2002064131A3 Inflammation-inhibiting compounds |